FDA Floats OTC Monograph Overhaul To Be “More Agile”
This article was originally published in The Tan Sheet
The agency will conduct a public hearing on March 25 and 26 for comments about improving the OTC monograph process, which currently faces “significant challenges.”
You may also be interested in...
Rx-to-OTC switch sponsors should not wait for FDA to act on NSURE before proposing innovative switch solutions, because reviewers are open to discussing ideas now, an agency official says. Some experts predict the new switch paradigm will not yield concrete regulatory changes, and are promoting other ways to expand OTC access.
Many monograph OTCs are overshadowed in the marketplace by NDA products and have much less space on store shelves. With some NDA-approved ingredients moved to monographs, FDA pre-market approval would no longer be required and more firms could make those products.
Brand’s management says its packaging redesign “was inspired by the Nature Made heritage and Nurish mission that healthy living should be joyful.” It partnered with branding consultancy Spicefire to develop brand and packaging to evoke Pharmavite’s 50 years of providing supplements.